- Home
- LNKB vs RIGL Comparison
LNKB vs RIGL Comparison
Compare LNKB & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LNKB
- RIGL
- Stock Information
- Founded
- LNKB 2018
- RIGL 1996
- Country
- LNKB United States
- RIGL United States
- Employees
- LNKB N/A
- RIGL N/A
- Industry
- LNKB
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- LNKB
- RIGL Health Care
- Exchange
- LNKB Nasdaq
- RIGL Nasdaq
- Market Cap
- LNKB 284.4M
- RIGL 486.4M
- IPO Year
- LNKB N/A
- RIGL 2000
- Fundamental
- Price
- LNKB $7.43
- RIGL $17.09
- Analyst Decision
- LNKB Hold
- RIGL Buy
- Analyst Count
- LNKB 1
- RIGL 5
- Target Price
- LNKB $7.50
- RIGL $34.80
- AVG Volume (30 Days)
- LNKB 68.0K
- RIGL 189.6K
- Earning Date
- LNKB 01-27-2025
- RIGL 11-07-2024
- Dividend Yield
- LNKB 4.02%
- RIGL N/A
- EPS Growth
- LNKB 61.51
- RIGL N/A
- EPS
- LNKB 0.17
- RIGL 0.22
- Revenue
- LNKB $86,138,000.00
- RIGL $157,374,000.00
- Revenue This Year
- LNKB N/A
- RIGL $48.98
- Revenue Next Year
- LNKB $9.49
- RIGL $14.43
- P/E Ratio
- LNKB $44.73
- RIGL $76.64
- Revenue Growth
- LNKB 151.51
- RIGL 21.65
- 52 Week Low
- LNKB $5.86
- RIGL $7.48
- 52 Week High
- LNKB $8.29
- RIGL $29.82
- Technical
- Relative Strength Index (RSI)
- LNKB 50.19
- RIGL 30.82
- Support Level
- LNKB $7.40
- RIGL $16.68
- Resistance Level
- LNKB $7.89
- RIGL $19.80
- Average True Range (ATR)
- LNKB 0.21
- RIGL 1.53
- MACD
- LNKB -0.05
- RIGL -1.05
- Stochastic Oscillator
- LNKB 17.24
- RIGL 3.66
About LNKB LINKBANCORP Inc.
Linkbancorp Inc operates in the banking industry. It provides banking services for individuals and businesses such as commercial lending, non-profit banking, treasury management, deposits and loans.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.